Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Richard Furie, Raj Tummala, Edward M Vital et al.|The Lancet Rheumatology|2019

Cited by 478